Search results
General guidelines for the treatment of women with von Willebrand disease at delivery. Since pregnant women with VWD are at increased risk of postpartum hemorrhage if untreated 9, 17, 27, 31, treatment options should be planned at the beginning of pregnancy.
- Table 1
Given the wide heterogeneity of phenotypes and of the...
- Mcmdm-1Vwd
Introduction. von Willebrand factor (VWF) is a multimeric...
- Table 1
May 20, 2019 · The variable pattern of changes observed during pregnancy of von Willebrand factor (VWF) and factor VIII (FVIII), the protein carried by VWF, prompts a careful evaluation of pregnant women with VWD to plan the most appropriate treatment at the time of parturition.
- Giancarlo Castaman, Paula D. James
- 2019
People also ask
Does von Willebrand disease affect pregnancy and childbirth?
How does von Willebrand disease affect women?
What is von Willebrand factor (vWF) and FVIII?
What causes von Willebrand disease (vWD)?
Jun 7, 2022 · Although VWD occurs equally in males and females, women are at a higher risk of being affected, mostly because of bleeding challenges associated with menstruation, pregnancy, and childbirth [ 1, 7, 8 ]. During pregnancy, many changes in hemostasis occur that result in a hypercoagulable state.
Pregnancy causes VWF levels to rise in most women, including many of those with VWD, which makes the disease harder to detect (Figure). As a result, the diagnostic evaluation must factor in a history of mucocutaneous bleeding and family history of VWD as well as abnormal results on VWF laboratory tests.
May 1, 2017 · During pregnancy, hormonal influences lead to an increase in vWF and clotting factors VII, VIII, and X while anticoagulant factors (such as protein S) decrease, shifting hemostasis to a procoagulant state to compensate for anticipated hemorrhage during parturition. 3 Although vWF and FVIII levels rise and peak during the third trimester, women w...
- Caroline Berube, Brian Dietrich
- 2017
Jan 1, 2022 · von Willebrand disease (VWD) disproportionately affects women because of the potential for heavy menstrual bleeding (HMB), delivery complications, and postpartum hemorrhage (PPH). To systematically synthesize the evidence regarding first-line management of HMB, treatment of women requiring or desiring neuraxial analgesia, and management of PPH.
Bleeding complications during pregnancy are more frequent when levels of the von Willebrand ristocetin cofactor assay and factor VIII levels are 50 IU/dL. In such cases, therapy before any invasive procedure or delivery must be instituted. The mainstays of therapy are desmopressin and plasma concentrates that contain von Willebrand factor.
